Medline Inc. (MDLN)
SEC filings, insider trading & institutional ownership from EDGAR.
Medline Inc. is the largest provider of medical-surgical (med-surg) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. Founded in 1966, the company states its mission as making healthcare run better by delivering improved clinical, financial and operational outcomes. It combines manufacturing, sourcing and distribution of med-surg products with supply chain services, supported by a Prime Vendor model, a distribution network and a commercial platform.
Medline has two reportable segments. The Medline Brand segment offers about 190,000 products under the Medline brand in three categories: Front Line Care (wound care, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, durable medical equipment and infection control products), Surgical Solutions (procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, gloves and orthopedic implants) and Laboratory and Diagnostics (point of care testing, analyzers, consumables, vital signs monitors, and pathology and phlebotomy products). The Supply Chain Solutions segment offers about 145,000 products from more than 1,300 third-party suppliers, including nearly all leading national brands. It also provides consulting, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization and route planning. Across both segments the company offers about 335,000 products. It holds more than 2,300 granted patents and more than 450 FDA 510(k) clearances, and has launched more than 250 new products in the last three years.
Customers range from hospitals and surgery centers to physician offices and post-acute facilities. Many are served through Prime Vendor relationships, which are multi-year agreements, typically five years, under which the customer buys the vast majority of its med-surg products from Medline. The company reports an average Prime Vendor retention rate above 98% over the past five years. A U.S. commercial team of about 4,000 people supports customers, with teams dedicated to each channel and each international region. No international market represents more than 3% of net sales.
Medline manufactures about one-third of its Medline Brand products, primarily Class I and II medical devices, in 30 manufacturing facilities, 24 of them in North America. It sources most of the rest from more than 600 partners in about 40 countries, with no single partner above 5% of spend. Its network has 70 distribution centers, warehouses, cross-docks and transship facilities, 45 in the United States, which provide next-day delivery to 95% of U.S. customers. It also runs more than 2,100 owned MedTrans trucks. Competitors include other med-surg manufacturers and distributors such as McKesson, Cardinal Health, Owens & Minor and Henry Schein. The company has over 45,000 employees, more than 26,000 in the United States, and is subject to extensive regulation, notably by the FDA.
AI-summarized from Item 1 (Business) of the company’s most recent 10-K filing.
Financials
As reported to the SEC via XBRL, no adjustments
| Gross profit | $7.52B |
| Operating income | $2.21B |
| Diluted EPS | -$0.01 |
| Gross margin | 26.4% |
| Net margin | 4.1% |
Revenue by region
FY2025 geographic segments • from the 10-K
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
| Form | Filed |
|---|---|
| 10-Q | Nov 4, 2026 |
| 8-K | Nov 4, 2026 |
| SC 13G/AamendedGIC Private Limited and 2 other reporting persons | Oct 30, 2026 |
| 8-K | Oct 21, 2026 |
Insider trading
From Form 4 filings
| Insider | Date | Type |
|---|---|---|
| Hux Investment Pte. Ltd. | Oct 8, 2026 | Sell |
| GIC Special Investments Pte Ltd | Oct 8, 2026 | Sell |
| GIC Private Ltd | Oct 8, 2026 | Sell |
| Hux Investment Pte. Ltd. | Oct 6, 2026 | Sell |
| Hux Investment Pte. Ltd. | Oct 6, 2026 | Sell |
Top holders
13F & 13D/G • latest quarter
| Holder | Stake | Filed | Value |
|---|---|---|---|
| FMR LLC | 5.3% | Aug 13, 2026 | $1.85B |
| Capital Research Global Investors | 4.5% | Aug 12, 2026 | $1.58B |
| Invesco Ltd. | 4.4% | Aug 14, 2026 | $1.51B |
| BlackRock, Inc. | 3.0% | Aug 7, 2026 | $1.04B |
| MORGAN STANLEY | 2.5% | Aug 13, 2026 | $852.13M |
The IPO at a glance
From the final prospectus (424B4), filed Dec 18, 2025 • listed on Nasdaq Global Select Market as “MDLN”
- Share classes
- Class A common stock • one voteClass B common stock • one vote
- Lock-up
- 180 days
- Led by
- Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC
Figures are quoted from the prospectus as printed.
What the money is for, the risk themes in the prospectus’s own terms, dilution to new investors, and the red-flag scan of the offering, verified against the filing.
Sign up free →Executive pay and the vote
From the FY2025 proxy statement (DEF 14A), filed Apr 23, 2026, and the annual meeting’s vote on Jun 11, 2026
Figures come from the company’s proxy statement, and the vote count from its 8-K.
The Summary Compensation Table for every named officer, the board with tenure and committees, and each proposal with its count, verified against the filings.
Sign up free →Latest 10-Q takeaways
filed Nov 4, 2026Management reports strong top-line growth (+10.4% net sales), lower interest expense and solid cash generation, but this is offset by a destructive distribution center fire, three unresolved FDA warning letters, a bed market exit and recall, tariff pressures, and gross margin compression. The tone is factual and mixed, with moderately confident mitigation and liquidity assertions, heavy risk disclosure, and a mostly backward-looking results discussion.
Written by Scrutar's AI from MDLN's SEC filings. Check anything you rely on against the filing. Not investment advice.
MDLN's filings are public. The insight is one click away.
Scrutar's AI reads every MDLN filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a MDLN filing.
Get an email when MDLN files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Companies related to MDLN
Peers identified from MDLN's own SEC filings.
Data as of Nov 8, 2026Source: SEC EDGAR.